SCHEMBL249202

SCHEMBL249202

NC(=O)c1cc[c]c2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.47
KMT2A Q03164 1/20 0.47
KDM4E B2RXH2 6/20 0.42
ALDH1A1 P00352 4/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 2/20 0.41
TSHR P16473 2/20 0.41
HSD17B10 Q99714 2/20 0.41
HPGD P15428 1/20 0.41
METAP2 P50579 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
BCAT2 O15382 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
POLB P06746 2/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GLA P06280 1/20 0.36
PARP1 P09874 2/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5746207 0.87 KDM4E (0.44) ATMKMT2AKDM4EALDH1A1GAA
SCHEMBL8904316 0.82 F2 (0.37) KMT2ARECQLBLM
SCHEMBL249780 0.82 NR4A1 (0.48) KMT2AKDM4EALDH1A1MAPTTSHR
SCHEMBL4319548 0.81 KDM4E (0.42) KMT2AKDM4EALDH1A1GAAMAPT
SCHEMBL5749003 0.80 KDM4E (0.59) ATMKMT2AKDM4EALDH1A1GAA
SCHEMBL5213229 0.78 AKR1C3 (0.46) ATMKMT2AKDM4EALDH1A1GAA
SCHEMBL8648602 0.77 NR4A2 (0.46) ATMKMT2AKDM4EALDH1A1TSHR
SCHEMBL11289604 0.74 GAA (0.53) KDM4EALDH1A1GAAMAPTNPC1
SCHEMBL28639283 0.74 ATM (0.75) ATMKMT2AKDM4EALDH1A1GAA
SCHEMBL8748348 0.73 TSHR (0.56) KDM4EALDH1A1GAATSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1339663-B1 NAPHTHALENE DERIVATIVES NOVARTIS AG (CH) 2012-01-04 EP claimed
EP-2243805-B1 ANTHRAPYRIDONE COMPOUND OR SALT THEREOF, MAGENTA INK COMPOSITION CONTAINING THE ANTHRAPYRIDONE COMPOUND, AND COLORED BODY NIPPON KAYAKU KK (JP) 2014-11-26 EP disclosed
CN-101925658-B Anthrapyridone compound or salt thereof, magenta ink composition containing anthrapyridone compound, and colored body NIPPON KAYAKU KK 2013-10-02 CN disclosed
EP-1339663-B1 NAPHTHALENE DERIVATIVES NOVARTIS AG (CH) 2012-01-04 EP disclosed
US-7985287-B2 Anthrapyridone compound or a salt thereof, magenta ink composition containing the anthrapyridone compound and colored product NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2011-07-26 US disclosed
EP-2338886-A2 Naphthalene derivatives Novartis AG (CH) 2011-06-29 EP disclosed
CN-101925658-A Anthrapyridone compound or salt thereof, magenta ink composition containing anthrapyridone compound, and colored body NIPPON KAYAKU KK 2010-12-22 CN disclosed
US-20100291360-A1 Anthrapyridone Compound Or A Salt Thereof, Magenta Ink Composition Containing The Anthrapyridone Compound and Colored Product NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2010-11-18 US disclosed
EP-2243805-A1 ANTHRAPYRIDONE COMPOUND OR SALT THEREOF, MAGENTA INK COMPOSITION CONTAINING THE ANTHRAPYRIDONE COMPOUND, AND COLORED BODY Nippon Kayaku Kabushiki Kaisha (JP) 2010-10-27 EP disclosed
US-20060293503-A1 Polyaminopyridines and method for producing same SUMITOMO SEIKA CHEMICALS CO., LTD (JP) 2006-12-28 US disclosed
EP-1669390-A1 POLYAMINOPYRIDINES AND METHOD FOR PRODUCING SAME SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2006-06-14 EP disclosed
US-7045533-B2 Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout NOVARTIS AG (CH) 2006-05-16 US disclosed
US-20060084657-A1 Piperazine derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2006-04-20 US disclosed
CN-1224598-C Naphthalene derivatives NOVARTIS AG (CH) 2005-10-26 CN disclosed
WO-2005058292-A1 NEW USE IN GASTROINTESTINAL DISORDERS ASTRAZENECA AB (SE) 2005-06-30 WO disclosed
EP-1468990-A1 PIPERAZINE DERIVATIVE Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-20 EP disclosed
US-20040053890-A1 Naphthalene derivatives NOVARTIS AG (CH) 2004-03-18 US disclosed
CN-1476424-A Naphthalene derivatives ��˹��ŵ�� 2004-02-18 CN disclosed
EP-1339663-A2 NAPHTHALENE DERIVATIVES Novartis AG (CH) 2003-09-03 EP disclosed
WO-2002042248-A2 NAPHTHALENE DERIVATIVES NOVARTIS AG (CH) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100291360-A1 Anthrapyridone Compound Or A Salt Thereof, Magenta Ink Composition Containing The Anthrapyridone Compound and Colored Product MLLT3, MLLT1, H1-3 ATM 407/4885KMT2A 434/4885KDM4E 469/4885
US-20040053890-A1 Naphthalene derivatives CYP1A1, SULT1E1, CYP2F1 ATM 4395/4885KMT2A 4193/4885KDM4E 3981/4885
US-20060084657-A1 Piperazine derivative MC2R, MC5R, MC4R ATM 2624/4885KMT2A 2170/4885KDM4E 2340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.